Cure My Disease

Don't miss your cure!

 Log in / Sign up

Foam could ease painful skin lumps in hidradenitis suppurativa

NCT ID NCT07689188

Not yet recruiting Disease control Sponsor: Harrison Dermatology Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests a medicated foam called roflumilast applied daily to hidradenitis suppurativa (HS) lesions for 16 weeks. It includes adolescents and adults with mild to moderate HS (Hurley stage I or II) who have 4 to 10 painful lumps or abscesses but no draining tunnels. The main goal is to see if the foam reduces the number of abscesses and inflamed nodules. This is an early, small trial to check safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Roflumilast 0.3% topical foam
What this could lead to
If effective, this foam could offer a new topical treatment option for hidradenitis suppurativa, reducing painful lumps and abscesses.
What could go wrong
This is a small early-phase trial with only 10 participants, so results may not apply widely. The foam may not work or could cause skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA (HS)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Harrison Dermatology

    Missouri City, Texas, 77459, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.